Clinical Disease Activity With Long Term Natalizumab Treatment

CompletedOBSERVATIONAL

Enrollment

277

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

August 18, 2016

Study Completion Date

August 18, 2016

Conditions

Relapsing-Remitting Multiple Sclerosis

Interventions

DRUG

natalizumab

Participants with RRMS receiving commercial natalizumab in Belgium and Czech Republic

Trial Locations (4)

Research Site 1, Brussels

Research Site 2, Brussels

Research Site, Overpelt

Research Site, Prague